Catalio Capital Management
$532M 13F equity value
52 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Catalio Capital Management covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| AVLN | AVALYN PHARMACEUTICALS INC | 1,675,830 | $55M | 10.4% |
| JNJ | JOHNSON & JOHNSON | 138,946 | $35M | 6.6% |
| GILD | GILEAD SCIENCES INC | 269,309 | $34M | 6.4% |
| BBIO | BRIDGEBIO PHARMA INC | 455,041 | $34M | 6.4% |
| SNDX | SYNDAX PHARMACEUTICALS INC | 1,215,698 | $27M | 5.0% |
| DFTX | DEFINIUM THERAPEUTICS INC | 562,672 | $26M | 5.0% |
| BMY | BRISTOL-MYERS SQUIBB CO | 412,961 | $24M | 4.5% |
| PBLS | PARABILIS MEDICINES INC | 824,043 | $23M | 4.2% |
| NTRA | NATERA INC | 82,181 | $22M | 4.2% |
| INCY | INCYTE CORP | 191,627 | $22M | 4.1% |
Track Catalio Capital Management's 13F portfolio: $532M in reported holdings, 52 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}